Stuttgart - Delayed Quote EUR

Halozyme Therapeutics Inc. (RV7.SG)

35.75

-0.09

(-0.25%)

As of 8:02 AM GMT+2. Market Open.

Mahesh Krishnan Elected to Halozyme's Board of Directors

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced the election of Mahesh Krishnan, M.D. to its Board of Directors. Dr. Krishnan has more than 20 years of experience in healthcare, biotechnology and health services.

PR Newswire 15 hours ago

HALO
Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks yesterday

HALO
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks 2 days ago

HALO
Halozyme to Report First Quarter 2024 Financial and Operating Results

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its first quarter 2024 financial and operating results on Tuesday, May 7, 2024, following the close of trading.

PR Newswire 2 days ago

HALO
Halozyme Therapeutics (HALO) is an Incredible Growth Stock: 3 Reasons Why

Halozyme Therapeutics (HALO) could produce exceptional returns because of its solid growth attributes.

Zacks 7 days ago

HALO
Halozyme Therapeutics (HALO) Upgraded to Buy: Here's What You Should Know

Halozyme Therapeutics (HALO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks 7 days ago

HALO
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks 20 days ago

HALO
Halozyme Therapeutics (HALO) is a Top-Ranked Value Stock: Should You Buy?

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks 21 days ago

HALO
Is Now The Time To Put Halozyme Therapeutics (NASDAQ:HALO) On Your Watchlist?

It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...

Simply Wall St. 22 days ago

HALO
Mirum Pharmaceuticals (MIRM) Down 12.5% Since Last Earnings Report: Can It Rebound?

Mirum Pharmaceuticals (MIRM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks 27 days ago

MIRM

HALO
The 3 Best Biotech Stocks to Buy in Q2 2024

Biotech is an industry full of opportunity. It’s also known as one of the riskiest sectors to invest in. Why is this the case? Well, many of these companies are very small and focused on researching new drugs. These drugs, being their products, are thus in development and thus the future revenue is not assured. The future revenue hinges on successful FDA approvals and the ability to actually sell the drug. As such, this industry is known for companies that tank 50% in just days following poor cl

InvestorPlace 28 days ago

HALO
Why Is Denali Therapeutics (DNLI) Up 2.8% Since Last Earnings Report?

Denali Therapeutics (DNLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks 28 days ago

DNLI

SNY

HALO
Fate Therapeutics (FATE) Down 8% Since Last Earnings Report: Can It Rebound?

Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks 29 days ago

FATE

HALO
Why Is Halozyme Therapeutics (HALO) Up 5.3% Since Last Earnings Report?

Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks last month

HALO

BPMC
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks last month

HALO
Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks last month

HALO
Insider Sell: SVP, Chief Technical Officer Michael Labarre Sells 20,000 Shares of Halozyme ...

Halozyme Therapeutics Inc (NASDAQ:HALO), a biopharmaceutical company focused on developing and commercializing novel oncology therapies that target the tumor microenvironment, has reported an insider sell according to a recent SEC filing.

GuruFocus.com last month

HALO
7 Biotech Stocks to Buy as Sector Rotation Ramps Up

While the technology sector has been enjoying ridiculous returns, it’s inevitable that a slowdown (or even a correction) may materialize, which brings to the table biotech stocks. This is just as innovative of sector as “regular” tech but it just hasn’t received the same fervor. That could soon change. With the usual suspects in the digital innovation arena soaring to new heights, the law of large numbers will eventually kick in. For investors to get the same rewards they’ve been used to will li

InvestorPlace last month

CYTK

CRSP

VKTX
Should You Hold Halozyme Therapeutics (HALO)?

Artisan Partners, an investment management company, released its “Artisan Small Cap Fund” fourth quarter 2023 investor letter. A copy of the same can be downloaded here. The portfolio had a positive absolute return in Q4 but underperformed the Russell 2000 Growth Index due to security selection, particularly in the healthcare and information technology sectors. In the […]

Insider Monkey last month

HALO

^RUT
Halozyme to Participate in Upcoming Investor Conferences

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, president and chief executive officer, is scheduled to present and host investor meetings at the following investor conferences:

PR Newswire last month

HALO

Performance Overview

Return	RV7.SG	MSCI WORLD
YTD	0.00%	+4.47%
1-Year	0.00%	+18.69%
3-Year	0.00%	0.00%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Halozyme Therapeutics Inc. (RV7.SG)

Mahesh Krishnan Elected to Halozyme's Board of Directors

Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

Halozyme to Report First Quarter 2024 Financial and Operating Results

Halozyme Therapeutics (HALO) is an Incredible Growth Stock: 3 Reasons Why

Halozyme Therapeutics (HALO) Upgraded to Buy: Here's What You Should Know

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

Halozyme Therapeutics (HALO) is a Top-Ranked Value Stock: Should You Buy?

Is Now The Time To Put Halozyme Therapeutics (NASDAQ:HALO) On Your Watchlist?

Mirum Pharmaceuticals (MIRM) Down 12.5% Since Last Earnings Report: Can It Rebound?

The 3 Best Biotech Stocks to Buy in Q2 2024

Why Is Denali Therapeutics (DNLI) Up 2.8% Since Last Earnings Report?

Fate Therapeutics (FATE) Down 8% Since Last Earnings Report: Can It Rebound?

Why Is Halozyme Therapeutics (HALO) Up 5.3% Since Last Earnings Report?

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock

Insider Sell: SVP, Chief Technical Officer Michael Labarre Sells 20,000 Shares of Halozyme ...

7 Biotech Stocks to Buy as Sector Rotation Ramps Up

Should You Hold Halozyme Therapeutics (HALO)?

Halozyme to Participate in Upcoming Investor Conferences

Performance Overview